Narsoplimab (Synonyms: OMS 721; Anti-MASP2 Reference Antibody (narsoplimab)) |
Catalog No.GC69538
One-Click Copy Product Info
|
Narsoplimab (anti-MASP-2) is a human immunoglobulin gamma 4 (IgG4) monoclonal antibody against mannose-binding protein-associated serine protease 2 (MASP-2) achieved by high affinity (zymogen form: KD=0.062nM, IC50~3.4nM; enzymatically active form: KD=0.089nM) to block lectin pathway.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2108782-45-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Narsoplimab (anti-MASP-2) is a human immunoglobulin gamma 4 (IgG4) monoclonal antibody against mannose-binding protein-associated serine protease 2 (MASP-2) achieved by high affinity (zymogen form: KD=0.062nM, IC50~3.4nM; enzymatically active form: KD=0.089nM) to block lectin pathway[1]. Narsoplimab selectively inhibits human C5b-9, IC50~1nM; its potency in cynomolgus monkey serum was IC50~33nM. The efficiency of Narsoplimab is EC50=6.1μg/mL ex vivo and IC50=33nM in vitro [1]. Narsoplimab shows positive potential results in hematopoietic stem-cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in a clinical trial[2].
In vitro experiments show that Narsoplimab act as a positive control to evaluate inhibitory efficiency among the N proteins of SARS-CoV, MERS-CoV and SARS-CoV-2(purified human MASP-2; 2.4μg/ml at 37°C; 3h)[3]. Moreover, MASP2 inhibition by Narsoplimab suppresses endotheliopathies characteristic of transplant-associated thrombotic microangiopathy (primary human neonatal microvascular endothelial cell; 10µg/ml; 5h)[4].
References:
[1] Dudler, Thomas et al. “Development and characterization of narsoplimab, a selective MASP-2 inhibitor, for the treatment of lectin-pathway-mediated disorders.” *Frontiers in immunology* vol. 14 1297352. 8 Nov. 2023, doi:10.3389/fimmu.2023.1297352
[2] Khaled, Samer K et al. “Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy.” *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* vol. 40,22 (2022): 2447-2457. doi:10.1200/JCO.21.02389
[3] Gao, Ting et al. “Highly pathogenic coronavirus N protein aggravates inflammation by MASP-2-mediated lectin complement pathway overactivation.” *Signal transduction and targeted therapy*vol. 7,1 318. 14 Sep. 2022, doi:10.1038/s41392-022-01133-5
[4]Elhadad, Sonia et al. “MASP2 inhibition by narsoplimab suppresses endotheliopathies characteristic of transplant-associated thrombotic microangiopathy: in vitro and ex vivo evidence.” Clinical and experimental immunology vol. 213,2 (2023): 252-264. doi:10.1093/cei/uxad055
| Cell experiment [1]: | |
Cell lines | primary human neonatal microvascular endothelial cell |
Preparation Method | Narsoplimab was planned for intravenous infusion at a dose of 4 mg/kg twice weekly in both adult and pediatric patients for at least 8 doses, on the basis of evidence that this dosage provided well greater than 80% inhibition of the lectin pathway. In case of incomplete response and in the absence of any toxicity, treatment could be prolonged with no limit to the number of infusions. For one patient, the dosage was increased to 3 times a week due to a poor initial response to the treatment. |
Reaction Conditions | 10µg/ml; 5h |
Applications | Narsoplimab suppressed transcripts encoding pro-apoptotic and pro-inflammatory proteins ZNF521, IL1R1, Fibulin-5, aggrecan, SLC14A1, and LOX1, and TMEM204, which disrupts vascular integrity. |
References: | |
| Cas No. | 2108782-45-0 | SDF | |
| Synonyms | OMS 721; Anti-MASP2 Reference Antibody (narsoplimab) | ||
| Formula | M.Wt | ||
| Solubility | Storage | Store at -80°C | |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
-
Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)